Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00078000 |
Assessment of safety and efficacy of SU11248 in patients with metastatic breast cancer who have failed selected other therapies.
Condition | Intervention | Phase |
---|---|---|
Breast Neoplasms |
Drug: SU011248 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Study Of The Efficacy And Safety Of SU011248 In Patients With Metastatic Breast Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
Greenbrae, California, United States, 94904 | |
Pfizer Investigational Site | |
Los Angeles, California, United States, 90095 | |
Pfizer Investigational Site | |
San Francisco, California, United States, 94115 | |
United States, Colorado | |
Pfizer Investigational Site | |
Aurora, Colorado, United States, 80010 | |
United States, Illinois | |
Pfizer Investigational Site | |
Chicago, Illinois, United States, 60612-3824 | |
United States, Indiana | |
Pfizer Investigational Site | |
Indianapolis, Indiana, United States, 46202 | |
United States, Maryland | |
Pfizer Investigational Site | |
Baltimore, Maryland, United States, 21231 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02114 | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02115 | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02215 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A6181002 |
Study First Received: | February 13, 2004 |
Last Updated: | November 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00078000 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Sunitinib Breast Neoplasms Breast Diseases |
Neoplasms Neoplasms by Site Antineoplastic Agents Growth Substances Therapeutic Uses |
Physiological Effects of Drugs Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions |